Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673

Cancer Letters

Volumn 364, Issue 1, 2015, Pages 8-16

  Andrei, Alexandra Zoe ^a,b   Hall, Anita ^a,b   Smith, Alyssa L ^a,b   Bascuñana, Claire ^a,b   Malina, Abba ^c   Connor, Ashton ^d   Altinel Omeroglu, Gulbeyaz ^e   Huang, Sidong ^c   Pelletier, Jerry ^a,d   Huntsman, David ^f   Gallinger, Steven ^d   Omeroglu, Atilla ^e   Metrakos, Peter ^b   Zogopoulos, George ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

BMN 673; BRCA2; DNA repair; Pancreatic ductal adenocarcinoma; Personalized medicine

Indexed keywords

BRCA2 PROTEIN; CARBOPLATIN; CASPASE 3; CISPLATIN; GEMCITABINE; HISTONE H2AX; OXALIPLATIN; RAD51 PROTEIN; SHORT HAIRPIN RNA; TALAZOPARIB; VELIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHTHALAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; GENE SILENCING; GENETICS; GERMLINE MUTATION; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TUMOR CELL LINE;

AGOUTI PACA; MURINAE;

CELL LINE, TUMOR; CISPLATIN; GENE KNOCKDOWN TECHNIQUES; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; IN VITRO TECHNIQUES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHTHALAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84929656428     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.04.003     Document Type: Article

References (35)

1. GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 385(9963):117-171.
2. Hidalgo M. Pancreatic cancer. N. Engl. J. Med 2010, 362:1605-1617.
3. Arslan C., Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J. Gastrointest. Oncol 2014, 5(4):280-295.
4. Biankin A.V., Waddell N., Kassahn K.S., Gingras M.C., Muthuswamy L.B., Johns A.L. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491(7424):399-405.
5. Abbotts R., Thompson N., Madhusudan S. DNA repair in cancer: emerging targets for personalized medicine. Cancer Manag. Res 2014, 6:77-92.
6. Shi C., Hruban R.H., Klein A.P. Familial pancreatic cancer. Arch. Pathol. Lab. Med 2009, 133(3):365-374.
7. Kobayashi H., Ohno S., Sasaki Y., Matsuura M. Hereditary breast and ovarian cancer susceptibility genes (review). Oncol. Rep 2013, 30(3):1019-1029.
8. Peng G., Lin S.Y. Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World J. Clin. Oncol 2011, 2(2):73-79.
9. Liu J.F., Konstantinopoulos P.A., Matulonis U.A. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol. Oncol 2014, 133(2):362-369.
10. Rowe B.P., Glazer P.M. Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res 2010, 12(2):203.
11. Conroy T., Dessigne F., Ychou M., Bouche O., Guimbaud R., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med 2011, 364:1817-1825.
12. Shen Y., Rehman F.L., Feng Y., Boshuizen J., Bajrami I., Elliott R. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin. Cancer Res 2013, 19(18):5003-5015.
13. Donawho C.K., Luo Y., Luo Y., Penning T.D., Bauch J.L., Bouska J.J. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res 2007, 13(9):2728-2737.
14. Moniri R., Young A., Reinheimer K., Rayat J., et al. Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA). Cytotechnology 2015, 67(2):379-386.
15. Broad Institute The RNAi Consortium shRNA Library [Online], accessed 11.11.14. http://www.broadinstitute.org/rnai/trc/lib.
16. Wilitzki A., Lorenz S., Hiemann R., Guttek K., Goihl A., Hartig R., et al. Fully automated analysis of chemically induced γH2AX foci in human peripheral blood mononuclear cells by indirect immunofluorescence. Cytometry A. 2013, 83(11):1017-1026.
17. Smith A.L., Bascuñana C., Hall A., Salman A., Andrei A.-Z., Volenik A., et al. Establishing of a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. Curr. Oncol 2015, 22:113-121.
18. Mayr N.A., Taoka T., Yuh W.T., Denning L.M., Zhen W.K., Paulino A.C. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys 2002, 52(1):14-22.
19. Sanceau J., Poupon M.F., Delattre O., Sastre-Garau X., Wietzerbin J. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene 2002, 21(50):7700-7709.
20. Albers J.W., Chaudhry V., Cavaletti G., Donehower R.C. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst. Rev 2014, (3). CD005228. 10.1002/14651858.CD005228.pub4.
21. Kobayashi S., Ueno M., Ohkawa S., Irie K., Goda Y., Morimoto M. Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary cancer. Oncology 2014, 87:30-39.
22. Hamada N., Schettino G., Kashino G., Vaid M., Suzuki K., Kodama S., et al. Histone H2AX phosphorylation in normal human cells irradiated with focused ultrasoft X rays: evidence for chromatin movement during repair. Radiat. Res 2006, 166(1 Pt 1):31-38.
23. Lodhia K.A., Gao S., Aleksic T., Esashi F., Macaulay V.M. Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition. Int. J. Cancer 2014, Epub ahead of print. 10.1002/ijc.29327.
24. Oberstein P.E., Olive K.P. Pancreatic cancer: why is it so hard to treat?. Therap. Adv. Gastroenterol 2013, 6(4):321-337.
25. Clark C.C., Weitzel J.N., O'Connor T.R. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol. Cancer Ther 2012, 11(9):1948-1958.
26. Lowery M.A., Kelsen D.P., Stadler Z.K., Kenneth H.Y., Janjigian Y., et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011, 16:1397-1402.
27. Golan T., Kanji Z.S., Epelbaum R., Devaud N., Dagan E., Holter S., et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br. J. Cancer 2014, 111:1132-1138.
28. Sy S.M., Huen M.S., Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl. Acad. Sci. USA 2009, 106(17):7155-7160.
29. Villarroel M.C., Rajeshkumar N.V., Garrido-Laguna I., De Jesus-Acosta A., et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol. Cancer Ther 2011, 10(1):3-8.
30. Smith M.A., Hampton O.A., Reynolds C.P., Kang M.H., Maris J.M., Gorlick R., et al. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr. Blood Cancer 2015, 62(1):91-98.
31. Lee J.M., Hays J.L., Annunziata C.M., Noonan A.M., Minasian L., et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J. Natl. Cancer Inst 2014, 106(6):dju089.
32. Kaufman B., Shapira-Frommer R., Schmutzler R.K., Audeh M.W., Friedlander M., et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol 2015, 33(3):244-250.
33. National Cancer Institute (NCI) Pilot trial of BMN 673, an oral PARP inhibitor, in patients with advanced solid tumors and deleterious BRCA mutations 2015, Last updated: February 7, ClinicalTrials.gov Identifier: NCT01989546.
34. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451(7183):1116-1120.
35. Lubinski J., Phelan C.M., Ghadirian P., Lynch H.T., Garber J., Weber B., et al. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam. Cancer 2004, 3(1):1-10.